术中多巴酚丁胺联合去甲肾上腺素预防脓毒症休克术后急性肾损伤的随机临床试验
这项在中国39家三级医院开展的随机开放标签试验纳入584例接受手术源控制的脓毒症休克成人患者,比较术中多巴酚丁胺联合去甲肾上腺素与单用去甲肾上腺素对术后7天内急性肾损伤的影响。结果显示联合组新发或加重AKI发生率为22.8%,低于单用组的34.7%(ARR 0.64,95%CI 0.49-0.83),且联合组术后第1天SOFA评分更低、干预后1小时尿量更高。
要点
- 术中多巴酚丁胺联合去甲肾上腺素可降低脓毒症休克术后7天内新发或加重AKI风险。
- 联合组2期和3期AKI发生率均低于单用去甲肾上腺素组。
- 联合组心动过速(心率>100次/分)发生率更高,需注意监测。
核心结论
- 在脓毒症休克接受手术源控制的成人患者中,术中多巴酚丁胺联合去甲肾上腺素较单用去甲肾上腺素降低术后7天内新发或加重AKI的发生率。
研究设计与样本
- 随机、开放标签临床试验,在中国39家三级医院开展,纳入2024年6月至2025年8月接受手术源控制的脓毒症休克成人患者,随访至2025年11月15日。
- 共584例患者,中位年龄67.5岁(IQR 55.0-76.0),女性192例(32.9%)。
- 干预为术中静脉输注多巴酚丁胺(最高5 µg/kg/min)联合去甲肾上腺素 vs 单用去甲肾上腺素。
主要发现
- 术后7天内新发或加重AKI在联合组发生22.8%(66/290),单用去甲肾上腺素组为34.7%(102/294),调整风险比(ARR)0.64(95%CI 0.49-0.83)。
- 11项次要结局中9项无显著差异;联合组术后第1天SOFA评分更低(调整差值-0.53,95%CI -0.98至-0.07),干预后1小时尿量更高(调整差值0.55,95%CI 0.03至1.07 mL/kg/h)。
- 联合组2期AKI发生4.8% vs 9.9%(ARR 0.48,95%CI 0.26-0.88),3期AKI发生7.9% vs 13.6%(ARR 0.56,95%CI 0.35-0.91)。
- 联合组心动过速(心率>100次/分)发生率高于单用去甲肾上腺素组。
关键数值与推荐
- 主要结局采用KDIGO标准定义术后7天内新发AKI或术前AKI加重。
- 多巴酚丁胺术中静脉输注剂量最高5 µg/kg/min。
临床怎么用
- 对于接受手术源控制的脓毒症休克成人患者,可考虑术中在多巴酚丁胺联合去甲肾上腺素方案以降低术后AKI风险。
- 联合用药时需监测心率,警惕心动过速发生。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: International guidelines recommend dobutamine for management of septic shock and cardiac dysfunction with persistent hypoperfusion in adults based on very low-certainty evidence. Randomized trials are lacking on the effect of intraoperative dobutamine combined with norepinephrine vs norepinephrine on postoperative outcomes in patients with septic shock undergoing surgical source control. OBJECTIVE: To determine whether intraoperative dobutamine combined with norepinephrine reduces acute kidney injury (AKI) within 7 postoperative days in patients with septic shock undergoing surgical source control. DESIGN, SETTING, AND PARTICIPANTS: This randomized, open-label clinical trial in 39 tertiary hospitals in China enrolled adults with septic shock who were undergoing surgical source control between June 2024 and August 2025. Follow-up ended on November 15, 2025. INTERVENTION: Intraoperative, intravenous infusion of dobutamine (up to 5 µg/kg/min) combined with norepinephrine vs norepinephrine alone. MAIN OUTCOMES AND MEASURES: The primary outcome was new-onset AKI or worsening of preoperative AKI within 7 days after surgery, defined using Kidney Disease: Improving Global Outcomes (KDIGO) criteria. The 11 secondary outcomes included Sequential Organ Failure Assessment (SOFA) score on postoperative day 1 and urine output 1 hour post intervention. RESULTS: Among 584 patients (median [IQR] age, 67.5 [55.0-76.0] years; 192 [32.9%] females), new-onset or worsening AKI within 7 postoperative days occurred in 22.8% (66/290) randomized to receive dobutamine plus norepinephrine vs 34.7% (102/294) randomized to receive norepinephrine alone (adjusted risk ratio [ARR], 0.64 [95% CI, 0.49-0.83]). No significant differences were observed in 9 of the 11 secondary outcomes. SOFA scores on postoperative day 1 (adjusted difference, -0.53 [95% CI, -0.98 to -0.07]) were lower and urine output 1 hour post intervention (adjusted difference, 0.55 [95% CI, 0.03 to 1.07] mL/kg/h) was higher in the dobutamine plus norepinephrine group. Stage 2 and 3 AKI were lower in the dobutamine plus norepinephrine group compared with the norepinephrine alone group (stage 2: 4.8% vs 9.9%; ARR, 0.48 [95% CI, 0.26-0.88]; stage 3: 7.9% vs 13.6%; ARR, 0.56 [95% CI, 0.35-0.91]). Tachycardia (heart rate >100/min) occurred more frequently in patients receiving dobutamine and norepinephrine than norepinephrine alone. CONCLUSIONS AND RELEVANCE: Among adult patients with septic shock undergoing surgical source control, intraoperative dobutamine combined with norepinephrine reduced the incidence of new-onset or worsening AKI within 7 postoperative days compared with norepinephrine. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT06462313.
引用
- Chu L, Xie G, Shi R, et al. Intraoperative Dobutamine Plus Norepinephrine to Prevent Postoperative Acute Kidney Injury in Septic Shock: A Randomized Clinical Trial. JAMA. 2026. PMID: 42872914. doi:10.1001/jama.2026.21322
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。